Checkpoint kinase 1 (Chk1), a serine/threonine kinase, plays an important role in DNA damage checkpoint control and is an attractive target for cancer treatment. To develop a Chk1-specific cell-based assay, stable clones were established in which Chk1 kinase domain fused at its N-terminus with p53 through 4 tandem repeats of Gly-Gly-Gly-Gly-Ser was expressed in an inducible manner. Chk1 kinase specificity of the phosphorylation of fused p53 was confirmed by the experiments with a kinase-inactive Chk1. Only in the presence of an inducer molecule was phosphorylation of p53 at Ser-15 in the stable clones induced. Furthermore, its assay performance proved acceptable for high-throughput screening applications, judging from the Z′ factor values (> 0.77). Finally, the cell-based assay thus established yielded structure-activity relationship data for a small set of test inhibitors of Chk1 within cells. Collectively, these results demonstrate that the established cell-based assay provides a novel and highly sensitive cellular platform for Chk1 inhibitor discovery. (Journal of Biomolecular Screening 2007:809-817)
Liu Q. , Guntuku S. , Cui XS , Cortez G. , Tamai K. , Luo G. , et al: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint . Genes Dev2000;14: 1448-1459 .
2.
Dixon H. , Norbury CJ : Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function . Cell Cycle2002;1: 362-368 .
3.
Tao ZF , Lin NH : Chk1 inhibitors for novel cancer treatment . Anticancer Agents Med Chem2006;6: 377-388 .
4.
Sausville EA , Arbuck SG , Messmann R. , Headlee D. , Bauer KS , Lush RM , et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms . J Clin Oncol2001 ;19: 2319-2333 .
5.
Ou YH , Chung PH , Sun TP , Shieh SY : p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation . Mol Biol Cell2005;16: 1684-1695 .
6.
Maki CG , Huibregtse JM , Howley PM : In vivo ubiquitination and proteasome-mediated degradation of p53(1) . Cancer Res1996;56: 2649-2654 .
7.
Honda R. , Yasuda H. : Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 . EMBO J1999 ; 18: 22-27 .
8.
Oren M. : Regulation of the p53 tumor suppressor protein . J Biol Chem1999;274: 36031-36034 .
9.
Ashcroft M. , Kubbutat MH , Vousden KH : Regulation of p53 function and stability by phosphorylation . Mol Cell Biol1999;19: 1751-1758 .
10.
Liu AM , Ho MK , Wong CS , Chan JH , Pau AH , Wong YH : Galpha(16/z) chimeras efficiently link a wide range of G protein-coupled receptors to calcium mobilization . J Biomol Screen2003 ;8: 39-49 .
11.
Storz P. , Doppler H. , Horn-Muller J. , Groner B. , Pfizenmaier K. , Muller G. : A cellular reporter assay to monitor insulin receptor kinase activity based on STAT 5-dependent luciferase gene expression . Anal Biochem1999; 276: 97-104 .
12.
Wood JM , Bold G. , Buchdunger E. , Cozens R. , Ferrari S. , Frei J. , et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration . Cancer Res2000;60: 2178-2189 .
13.
Quinones A. , Rainov NG : Identification of genotoxic stress in human cells by fluorescent monitoring of p53 expression . Mutat Res2001;494: 73-85 .
14.
Dikov MM , Reich MB , Dworkin L. , Thomas JW , Miller GG : A functional fibroblast growth factor-1 immunoglobulin fusion protein . J Biol Chem1998;273: 15811-15817 .
15.
Sakurai H. , Nishi A. , Sato N. , Mizukami J. , Miyoshi H. , Sugita T. : TAK1-TAB1 fusion protein: a novel constitutively active mitogen-activated protein kinase kinase kinase that stimulates AP-1 and NF-kappaB signaling pathways . Biochem Biophys Res Commun2002;297: 1277-1281 .
16.
Zheng C. , Xiang J. , Hunter T. , Lin A. : The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity . J Biol Chem1999;274: 28966-28971 .
17.
Zentrich E. , Han SY , Pessoa-Brandao L. , Butterfield L. , Heasley LE : Collaboration of JNKs and ERKs in nerve growth factor regulation of the neurofilament light chain promoter in PC12 cells . J Biol Chem2002; 277: 4110-4118 .
18.
Huston JS , Levinson D. , Mudgett-Hunter M. , Tai MS , Novotny J. , Margolies MN , et al: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli . Proc Natl Acad Sci U S A1988;85: 5879-5883 .
19.
Hazen RJ , Harvey RJ , St. Clair MH , Ferris RG , Freeman GA , Tidwell JH , et al: Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance . Antimicrob Agents Chemother2005;49: 4465-4473 .
Suda M. , Ishii T. , Sootome H. , Shibahara M. , Yamashita K. , Nobuhiro N. , et al: Cell-based screening for specifically detecting kinase activity . Biotechniques. Forthcoming.
22.
Zhao B. , Bower MJ , McDevitt PJ , Zhao H. , Davis ST , Johanson KO , et al: Structural basis for Chk1 inhibition by UCN-01 . J Biol Chem2002; 277: 46609-46615 .
23.
Warren GL , Andrews CW , Capelli AM , Clarke B. , LaLonde J. , Lambert MH , et al: A critical assessment of docking programs and scoring functions . J Med Chem2006;49: 5912-5931 .
24.
Yue TL , Gu JL , Wang C. , Reith AD , Lee JC , Mirabile RC , et al: Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy . J Biol Chem2000;275: 37895-37901 .
25.
Wang XJ , Liefer KM , Tsai S. , O'Malley BW , Roop DR : Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis . Proc Natl Acad Sci U S A1999;96: 8483-8488 .
26.
Zhang JH , Chung TD , Oldenburg KR : A simple statistical parameter for use in evaluation and validation of high-throughput screening assays . J Biomol Screen1999;4: 67-73 .
27.
Cheng Y. , Prusoff WH : Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction . Biochem Pharmacol1973;22: 3099-3108 .
28.
Knight ZA , Shokat KM : Features of selective kinase inhibitors . Chem Biol2005;12: 621-637 .
29.
Kubbutat MH , Vousden KH : Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability . Mol Cell Biol1997;17: 460-468 .
30.
Oliner JD , Pietenpol JA , Thiagalingam S. , Gyuris J. , Kinzler KW , Vogelstein B. : Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 . Nature1993;362: 857-860 .
